Memorial Hospital

Running trials

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Source

• Recruiting

  Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

  NCT07227012· Phase 1/2· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Active, not recruiting

  A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

  NCT06157892· Phase 2· Source

• Active, not recruiting

  TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

  NCT05548127· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

  NCT03915951· Phase 2· Source